Please assess the completion status of the following clinical trial:

Trial Title: IFCT-GFPC 05.02 A Randomized Phase III Trial Assessing in Patients With Advanced Non-small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically documented NSCLC (tumor tissue samples will be provided to look for assessment of EGFR status with CISH, immunochemistry and mutations) : adenocarcinoma, squamous cell carcinoma, large cell carcinoma. A cytological documentation of NSCLC is accepted.~* Stage IV disease or metastatic relapse in not previously irradiated areas of a NSCLC previously treated with surgery or radiation therapy (with a histologically documented proof of relapse) or stage III B with documented pleural involvement.~* Measurable disease according to the RECIST criteria.~* Prior radiotherapy authorized except for irradiation concerning measurable disease.~* Age \>18 and \< 70 years.~* PS \< 2.~* Normal hepatic function : serum bilirubin \< 1.5 ULN, SGOT (ASAT) and SGPT (ALAT) \< 2,5 ULN ; in presence of liver metastases, SGOT and SGPT must be \< 5 x ULN.~* Creatinine clearance \> 60 mL/min.~* Granulocyte count \> 1,5 giga/L, platelet count \> 100 giga/L.~* Life expectancy \> 12 weeks.~* Written (signed) informed consent for use of tumors samples.~* Written (signed) informed consent to participate in the sudy.~Exclusion Criteria:~* Small cell lung cancer, bronchiolo-alveolar carcinoma, neuro-endocrine carcinoma.~* PS \> 1.~* Prior chemotherapy other than cisplatin-gemcitabine.~* Prior therapy with EGFR inhibitor (e.g. monoclonal antibody).~* No concomitant therapy with phenytoin, carbamazepine, rifampicine or phenobarbital.~* Concomitant radiotherapy except for localized bone irradiation.~* Symptomatic brain metastases.~* Superior vena cava syndrome.~* Any unstable systemic disease : significant cardiovascular disease including myocardial infarction within the previous year, active infection, significant hepatic or renal disease.~* Pre-existing interstitial lung disease.~* Any inflammatory changes of the surface of the eyes.~* Psychiatric disease with inability to understand the study or to comply with follow-up procedures.~* Grade \> or = 2 peripheral neuropathy.~* Any other malignancies within 5 years (except for treated carcinoma in situ of the cervix or basal cell skin cancer).~* Pregnant or lactating women ; patients with reproductive potential must use effective contraception.~* Inability to comply with follow-up procedures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- A (supervision) (Type: SHAM_COMPARATOR): medical supervision, second line chemotherapy if progression
- B (gemcitabicine) (Type: ACTIVE_COMPARATOR): Maintenance treatment (gemcitabicine 1250 mg/m² J1, J8 (repeated cycles every 21 days), second line chemotherapy if progression
- C (Erlotinib) (Type: EXPERIMENTAL): Treatment by erlotinib 150 mg/day (sequential treatment), second line chemotherapy if progression

Based on this trial design, predict the completion outcome and termination type (if applicable).